Financial Review: Second Sight Medical Products (EYES) vs. OBALON THERPTCS (NASDAQ:OBLN)

OBALON THERPTCS (NASDAQ: OBLN) and Second Sight Medical Products (NASDAQ:EYES) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Profitability

This table compares OBALON THERPTCS and Second Sight Medical Products’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OBALON THERPTCS -566.87% -108.07% -48.50%
Second Sight Medical Products -646.89% -168.49% -129.48%

Analyst Recommendations

This is a breakdown of recent recommendations for OBALON THERPTCS and Second Sight Medical Products, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OBALON THERPTCS 1 0 3 0 2.50
Second Sight Medical Products 0 0 1 0 3.00

OBALON THERPTCS presently has a consensus target price of $15.25, suggesting a potential upside of 57.87%. Second Sight Medical Products has a consensus target price of $5.00, suggesting a potential upside of 342.48%. Given Second Sight Medical Products’ stronger consensus rating and higher possible upside, analysts plainly believe Second Sight Medical Products is more favorable than OBALON THERPTCS.

Valuation & Earnings

This table compares OBALON THERPTCS and Second Sight Medical Products’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
OBALON THERPTCS $4.98 million 32.63 -$27.12 million ($6.90) -1.40
Second Sight Medical Products $5.14 million 12.49 -$32.85 million ($0.72) -1.57

OBALON THERPTCS has higher revenue, but lower earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than OBALON THERPTCS, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

45.0% of OBALON THERPTCS shares are held by institutional investors. Comparatively, 13.1% of Second Sight Medical Products shares are held by institutional investors. 16.4% of OBALON THERPTCS shares are held by insiders. Comparatively, 50.9% of Second Sight Medical Products shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

OBALON THERPTCS beats Second Sight Medical Products on 7 of the 12 factors compared between the two stocks.

OBALON THERPTCS Company Profile

Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

Receive News & Ratings for OBALON THERPTCS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OBALON THERPTCS and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.